FDA Rejection of Rare Disease Therapy Sparks Debate Over Agency Direction A promising cell therapy developed by Atara Biotherapeutics and Pierre Fabre Pharmaceuticals for a rare blood cancer faced a sudden reversal in its path to FDA approval. Internal reviewers had previously recommended clearance, yet the agency rejected the drug last month, citing insufficient clinical … Read more
GSK’s $950 Million Bet on 35Pharma: A New Wave in Pulmonary Hypertension Treatment? GSK has acquired privately held 35Pharma for $950 million, a move signaling increased industry focus on pulmonary arterial hypertension (PAH). The acquisition centers around HS235, an experimental drug poised to enter clinical trials for PAH, a condition characterized by high blood pressure … Read more
Medicare Drug Price Battles: What Trump’s Plans Mean for Your Wallet The pharmaceutical industry is bracing for potential showdowns with the Trump administration over proposals designed to lower Medicare drug costs. These plans, centered around aligning U.S. Prices with those paid in other developed nations, could dramatically reshape the landscape of prescription drug affordability. But … Read more
Novo Nordisk’s Price Cuts: A Turning Point for GLP-1 Medications? Novo Nordisk’s announcement of significant price reductions for its blockbuster GLP-1 medications – Ozempic, Rybelsus and Wegovy – has sent ripples through the healthcare industry. The move, slated to take effect January 1, 2027, will lower the list price of each drug to $675 per … Read more
Bayer Challenges J&J’s Erleada Marketing Claims in Court German pharmaceutical company Bayer has launched a lawsuit against Johnson & Johnson (J&J) and its subsidiary Janssen Biotech, alleging false advertising related to their prostate cancer drugs, Erleada and Nubeqa. The legal action, filed in the United States District Court for the Southern District of New York, … Read more
Novo Nordisk’s Setback: What the CagriSema Trial Means for the Future of Obesity Drugs Novo Nordisk’s stock experienced a significant 15% drop on Monday after announcing its next-generation weight loss drug, CagriSema, did not demonstrate superiority to Eli Lilly’s tirzepatide in a recent trial. This news arrives as Eli Lilly’s drugs, Mounjaro and Zepbound, are … Read more
The AI Doctor is In: How Artificial Intelligence is Poised to Reshape Healthcare The future of healthcare is rapidly evolving and at the forefront of this transformation is artificial intelligence (AI). What was once the realm of science fiction is now becoming a tangible reality, with AI poised to take on tasks traditionally performed by … Read more
The CMO Shuffle: Why Leadership Changes are Accelerating in Biotech and Pharma The biopharmaceutical industry is experiencing a period of significant leadership transition. Recent moves, like CDR-Life’s appointment of Dimitrios Chondros as Chief Medical Officer (CMO), signal a broader trend of companies recalibrating their strategies and seeking specialized expertise to navigate a rapidly evolving landscape. … Read more
FDA Tightens the Leash on Livestock Antibiotics: What’s Next for Animal Health and Human Safety? The Food and Drug Administration (FDA) is taking a firmer stance on antibiotic utilize in food-producing animals, recently issuing guidance for drugmakers to define clear duration limits for medically important antibiotics. This move, announced February 12th by the FDA’s Center … Read more
FDA Reversal Paves the Way for Moderna’s mRNA Flu Vaccine The US Food and Drug Administration (FDA) has reversed its initial decision and will now review Moderna’s application for its innovative messenger RNA (mRNA)-based flu vaccine. This dramatic shift comes after a contentious back-and-forth with the pharmaceutical company, initially sparked by concerns over the clinical … Read more